Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

NCT01286987 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Recurrent Solid Tumors
Breast Neoplasms
Ovarian Cancer, Epithelial
Ewing Sarcoma
Small Cell Lung Carcinoma
Prostate Cancer
Pancreas Cancer

Interventions

DRUG: Talazoparib

Sponsor

Pfizer

Collaborators

[object Object]